当前位置:首页 - 行情中心 - 天坛生物(600161) - 财务分析 - 利润表

天坛生物

(600161)

  

流通市值:472.76亿  总市值:472.76亿
流通股本:16.48亿   总股本:16.48亿

利润表

报告期2023-12-312023-09-302023-06-302023-03-31
公司类型通用通用通用通用
一、营业总收入5,180,441,799.764,022,002,501.052,690,961,828.651,291,975,871.24
营业收入5,180,441,799.764,022,002,501.052,690,961,828.651,291,975,871.24
二、营业总成本3,429,763,630.822,618,355,943.431,784,099,100.49883,395,917.16
营业成本2,550,720,565.862,026,717,917.671,384,891,130.84697,682,745.78
税金及附加48,639,863.9439,036,600.1126,470,792.7811,164,287.17
销售费用270,516,563.02198,706,738.14152,953,306.7269,381,858.11
管理费用469,461,905.96329,484,614.96215,554,763.79101,877,571.37
研发费用139,949,764.2458,350,420.225,892,769.659,539,026.33
财务费用-49,525,032.2-33,940,347.65-21,663,663.29-6,249,571.6
其中:利息费用3,654,642.644,046,269.62,659,574.415,592,309.93
其中:利息收入55,526,126.6739,526,970.5325,364,806.2212,005,908.64
加:投资收益37,213,444.4426,978,444.4616,743,444.438,437,500
资产处置收益-51,775.39-2,085.3-2,085.3-
资产减值损失(新)-2,166,905-374,756.58-173,026.83-147,074.46
信用减值损失(新)-2,010,176.36-1,349,600.16-462,116.94872,201.59
其他收益21,331,808.5413,351,350.6511,649,901.499,614,090.82
营业利润平衡项目0000
四、营业利润1,804,994,565.171,442,249,910.69934,618,845.01427,356,672.03
加:营业外收入5,004,027.031,797,697.741,037,712.04688,544.54
减:营业外支出11,400,152.552,995,823.21598,225.5793,015.87
利润总额平衡项目0000
五、利润总额1,798,598,439.651,441,051,785.22935,058,331.48427,952,200.7
减:所得税费用289,139,647.24233,435,461.56160,856,568.0968,969,638.72
六、净利润1,509,458,792.411,207,616,323.66774,201,763.39358,982,561.98
持续经营净利润1,509,458,792.411,207,616,323.66774,201,763.39358,982,561.98
归属于母公司股东的净利润1,109,888,597.22887,400,407.26566,799,608.15261,909,016.67
少数股东损益399,570,195.19320,215,916.4207,402,155.2497,073,545.31
(一)基本每股收益0.670.540.340.16
(二)稀释每股收益0.670.540.340.16
九、综合收益总额1,509,458,792.411,207,616,323.66774,201,763.39358,982,561.98
归属于母公司股东的综合收益总额1,109,888,597.22887,400,407.26566,799,608.15261,909,016.67
归属于少数股东的综合收益总额399,570,195.19320,215,916.4207,402,155.2497,073,545.31
公告日期2024-03-292023-10-262023-08-302023-04-25
审计意见(境内)标准无保留意见
TOP↑